Cell Gene Therapy Bioprocessing Demand For Better Process Control Expertise CMOs
Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc. Manufacturing capacity for both cellular therapies and gene therapy viral vectors remains in short supply. From our research, including interviews with developers, there is a current and worsening capacity crunch. BioPlan Associates, Inc. annually surveys biopharmaceutical manufacturing professionals and publishes data on capacity and other industry concerns. 1 The survey, now in its 18 th year, includes 147 end users’ responses and also pr...